PRiiMO

Company Overview

Snapshot

Founded in March 2019 by Amit Gilboa, Prof. Philip Stricker, and Arnon Yaar, PRiiMO operates with 1–10 employees. The company raised $2 million across one funding round from two investors. PRiiMO ceased operations in June 2023.

Business overview

PRiiMO developed a digital platform that leverages an AI-based precision medicine engine to personalize cancer treatment plans for patients and their physicians. The platform integrates diverse data sources, including medical records, genomics, imaging, and patient behavior, to generate data analytics and actionable insights. Initially focusing on prostate cancer, PRiiMO aimed to serve urologists and their patients while building a comprehensive multi-source data asset for the disease. The company's mission was to personalize prevention, screening, diagnosis, monitoring, treatment, and post-treatment to minimize risk and costs, and maximize healthy life years.

Company Intelligence Q&A

What is PRiiMO's primary focus?

PRiiMO focuses on developing an AI-based precision medicine engine to personalize cancer treatment plans for patients and physicians, initially targeting prostate cancer.

When was PRiiMO founded and by whom?

PRiiMO was founded in March 2019 by Amit Gilboa, Prof. Philip Stricker, and Arnon Yaar.

What is the operational status of PRiiMO?

PRiiMO ceased to operate in June 2023.

What technology does PRiiMO utilize?

PRiiMO utilizes Artificial Intelligence and Machine Learning to power its precision medicine engine.

Which markets does PRiiMO serve?

PRiiMO serves geomarkets including the United States and Australia.